Distribution of SERPINA1 variants in chronic obstructive pulmonary disease, bronchiectasis, and the combined phenotype: a single-center cross-sectional study
This single-center cross-sectional study of 500 Turkish patients reveals that AATD-associated SERPINA1 variants are significantly more prevalent in the combined COPD-bronchiectasis phenotype (7.5%) than in COPD alone (2.1%) or bronchiectasis alone (0%), highlighting the clinical importance of this specific phenotype and the necessity for broader genotypic screening beyond classical variants.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Inside the human body, a protein called alpha-1 antitrypsin acts as a protective shield for the lungs. Its job is to stop the immune system from accidentally damaging lung tissue while it fights off infections. When a person inherits a specific genetic variation that prevents the body from making enough of this shield, the lungs can become vulnerable to early and severe damage. This condition, known as alpha-1 antitrypsin deficiency, is a well-understood cause of chronic obstructive pulmonary disease, or COPD, a condition where the airways become narrowed and breathing becomes difficult. It is also linked to bronchiectasis, a separate problem where the airways become permanently widened and scarred, making it hard to clear mucus. While doctors know to check for this deficiency in patients with COPD, the picture becomes murkier when a patient suffers from both conditions at the same time. Understanding how these genetic variations appear in people with this combined mix of lung diseases could help doctors identify who needs treatment sooner.
Researchers at Balıkesir Atatürk City Hospital in Turkey set out to map exactly how common these genetic variations are in three distinct groups of patients: those with only COPD, those with only bronchiectasis, and those suffering from both conditions simultaneously. Over a period of four years, they recruited 500 adults who had been evaluated for these respiratory issues. To find the genetic clues, the team did not need to draw large amounts of blood; instead, they collected tiny drops of blood from the patients' fingertips onto special filter paper. They then used a precise laboratory test to scan these samples for fourteen different known genetic variations that are linked to the deficiency. This approach allowed them to see the genetic makeup of each patient without invasive procedures.
The results revealed a clear pattern in how these genetic variations distribute across the different patient groups. Out of the 500 people studied, only 13 carried a variation associated with the deficiency, representing a small fraction of the total group. However, when the researchers looked closer at where these 13 individuals belonged, a striking difference emerged. None of the 51 patients who had bronchiectasis alone carried the variation. In the group of 382 patients with only COPD, the variation appeared in about two out of every hundred people. But in the group of 67 patients who had both COPD and bronchiectasis, the variation was found in nearly eight out of every hundred people. This suggests that the combination of these two lung diseases might be a stronger signal for the presence of this genetic issue than either disease is on its own.
The study also examined the specific types of genetic variations found. The most common one was a mix of a normal gene and a specific defective gene, followed by other rarer combinations. Interestingly, no one in the study had two copies of the most severe defective gene, which is often the case in the most extreme forms of the disease. When the researchers looked at the lungs of the patients who did carry these variations, they found that every single one of them had signs of emphysema, a condition where the tiny air sacs in the lungs are destroyed. Most of these patients showed a specific pattern of damage that spreads through the entire air sac, rather than just the center. This finding reinforces the idea that these genetic variations are actively damaging the lung structure, even in patients who might not have the most severe form of the deficiency.
The researchers also measured the levels of the protective protein in the blood of those with the variations. The levels were generally low, hovering near the bottom of the normal range, which aligns with the presence of the genetic variations. Some of these patients also showed signs of liver changes or higher pressure in the blood vessels leading to the lungs, though the study design did not allow the team to prove that the genetic variation caused these specific issues directly. The team noted that their study had limitations, such as the fact that they only tested for fourteen known variations and did not sequence the entire gene, meaning some very rare or new variations might have been missed. Additionally, the group of patients with only bronchiectasis was relatively small, which might have made it harder to find variations in that specific group.
Despite these limitations, the study points to a practical takeaway for medical care. The higher frequency of these genetic variations in patients with both COPD and bronchiectasis suggests that this specific group of patients should not be overlooked when doctors are screening for alpha-1 antitrypsin deficiency. Furthermore, the variety of different genetic variations found in the study indicates that doctors cannot rely on checking for just the two most common types of mutations. To truly understand a patient's risk, a broader look at their genetic code is necessary. By identifying these patients more accurately, the medical community can better understand who is at risk and potentially offer targeted care to protect their lungs from further damage.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.